Glenmark Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Progesterone Vaginal Inserts, 100 mg, marking a significant regulatory milestone for the pharmaceutical company. The FDA determined the product to be bioequivalent and therapeutically equivalent to the reference listed drug Endometrin® Vaginal Inserts, 100 mg of Ferring Pharmaceuticals Inc.

Regulatory Achievement and Market Entry

The FDA approval represents a major achievement in Glenmark's U.S. market expansion strategy. The company's progesterone vaginal inserts will be distributed in the United States by Glenmark Pharmaceuticals Inc., USA, providing direct access to this therapeutic market segment.

Market Opportunity and Commercial Potential

According to IQVIA® sales data for the 12-month period ending February 2026, the Endometrin® Vaginal Inserts, 100 mg market achieved annual sales of approximately $59.20 million. This substantial market size underscores the commercial significance of Glenmark's regulatory success in the women's healthcare segment.

Strategic Impact on Women's Healthcare Portfolio

Marc Kikuchi, President & Business Head, North America, emphasized the company's commitment to expanding access to quality and affordable medicines. "This approval for Progesterone Vaginal Inserts, 100 mg marks an important addition to our business and reinforces our focus on addressing patient needs in women's healthcare," Kikuchi stated.

The approval strengthens Glenmark's position in the competitive U.S. pharmaceutical market, particularly enhancing its women's healthcare product portfolio. This regulatory milestone demonstrates the company's capability to successfully navigate the stringent FDA approval process while maintaining focus on therapeutic equivalence and quality standards.

Glenmark Pharmaceuticals has received a significant GST adjudication order from tax authorities, demanding over ₹32.00 crore in alleged dues related to a brand sale transaction. The pharmaceutical company disclosed this development to stock exchanges on April 1, 2026, under regulatory compliance requirements.

GST Demand Details

The Joint Commissioner of Central Goods & Service Tax and Central Excise, Mumbai East Commissionerate, passed the adjudication order under sections 74 and 122 of the Central Goods and Services Tax Act, 2017. The order was issued on March 26, 2026, and received by the company via email on March 31, 2026.

Nature of Alleged Violation

The tax authorities have alleged that Glenmark's transaction involving the sale of a brand in FY 2020-21 should be treated as a "mixed supply" and therefore subject to a higher GST rate. This reclassification forms the basis of the demand for additional tax payment.

The order specifically demands:

• ₹16,05,41,509 on account of CGST/SGST allegedly short-paid by the company
• Applicable interest on the above tax amount
• ₹16,05,41,509 as penalty, equivalent to the alleged short-paid tax amount

Company's Response and Impact Assessment

Glenmark Pharmaceuticals has firmly rejected the tax demand, stating that based on the relevant facts of the case, it does not accept the allegations. The company has announced its intention to file an appeal before the appropriate authority to contest the order.

The company has assessed that there is no material impact on its financials, operations, or other activities due to the adjudication order. This disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which requires listed companies to inform exchanges about regulatory actions and inspections.

Regulatory Compliance

The disclosure follows the mandatory requirements under SEBI listing regulations for transparency regarding regulatory actions. The company has provided detailed information as required under Regulation 30 and Part A of Schedule III of the SEBI Listing Regulations, ensuring full compliance with disclosure norms for listed entities.